Novavax’s Phase 3 COVID-19 vaccine trial results suggest the vaccine may be applicable for distribution. Results show the two-shot vaccine is effective in preventing symptomatic infections, severe illness, and hospitalizations.
The study was conducted on 30,000 adults. 77 participants contracted COVID-19, only 14 of which were in the group that received the vaccine (the others were given a fake vaccine). None of the vaccine group participants experienced severe side effects. According to Novavax, the vaccine trial suggests a 90% effectiveness against lab-proven symptomatic infection and 93% against virus variants.
These rates are in the same range as vaccines produced by Pfizer-BioNTech and Moderna. However, these vaccines are still under review for full Food and Drug Administration approval. Currently, the FDA has only approved COVID-19 vaccines for emergency use. Since the US has been successful in producing and distributing vaccines, the Novavax vaccine seeks to aid the international community. “Many of our first doses will go to … low- and middle-income countries, and that was the goal to begin with,” Novavax CEO Stanley Erck said.
ARTICLE: ANTOINETTE AHO
MANAGING EDITOR: CARSON CHOATE
PHOTO CREDITS: ABC NEWS
Latest posts by Antoinette Aho (see all)
- House Democrats block Iron Done money from government funding bill - September 27, 2021
- DHS temporarily suspends use of horse units in Del Rio amid backlash - September 27, 2021
- New York City to enforce $50 fines for maskless transit riders - September 27, 2021